Skip to content

Ayahuasca: all studies

Page 10 of 167: studies 91 to 100 of 1,661, newest first. Back to the ayahuasca overview

Research

Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells

Archives of Toxicology November 12, 2025 Gilles Salles, Carolina Aparecida de Faria Almeida, Isabella de Carvalho Alves et al.

Ayahuasca is a psychoactive brew traditionally used in religious rituals by indigenous Amazonian populations and South American syncretic religions such as Santo Daime and União do Vegetal. Its psychoactive effects are primarily due to N,N-dimethyltryptamine (DMT), while harmine (HRE), a β-carboline alkaloid, inhibits monoamine oxidase (MAO), enabling DMT's oral bioavailability. Recent studies...

DOI: 10.1007/s00204-025-04208-8 (opens in new tab) Ayahuasca Harmine Apoptosis Flow cytometry +13

Intact neurophysiological markers of death denial in long-term ayahuasca users

Psychopharmacology November 10, 2025 Yair Dor-Ziderman, Jonathan David, Aviva Berkovich-Ohana

These findings provide preliminary evidence that while ayahuasca may alter how humans interact with the theme of death on conceptual and affective levels of cognitive processing, on automatic, perceptual unconscious levels of self-specific processing, death-denial processes appear to remain intact.

DOI: 10.1007/s00213-025-06963-z (opens in new tab) Full text (opens in new tab) Ayahuasca Unconscious mind Cognition Denial +5

Development of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans.

Toxicological sciences : an official journal of the Society of Toxicology November 1, 2025 Naphat Wittayakarn, Yu-Mei Tan, Pattanachai Choomalaiwong et al.

Ayahuasca is a traditional Amazonian brew composed of Psychotria viridis, containing N,N-dimethyltryptamine (DMT), and Banisteriopsis caapi, which includes harmala alkaloids such as harmine. Ayahuasca can produce potent psychoactive effects primarily due to DMT, whose metabolism is inhibited by harmine via monoamine oxidase-A enzymes. This inhibition increases DMT's systemic bioavailability,...

DOI: 10.1093/toxsci/kfaf118 (opens in new tab) Full text (opens in new tab) Ayahuasca Banisteriopsis caapi Psychotria viridis N,N-Dimethyltryptamine +2

Ayahuasca prevents the reinstatement of cocaine-induced rewarding effects in C57Bl/6 mice.

Psychopharmacology October 31, 2025 Vítor Bruno, Lídia Emmanuela Wiazowski Spelta, Matheus Lujan Pereira et al.

Ayahuasca is a brew containing the psychedelic compound N,N-dimethyltryptamine (DMT) and β-carbolines, traditionally consumed in indigenous rituals. Recent studies suggest its potential to reduce depression and anxiety and as an alternative for treating ethanol and tobacco use disorders. However, research on its impact on cocaine use disorder remains limited. To analyze the rewarding effects of...

DOI: 10.1007/s00213-025-06946-0 (opens in new tab) Full text (opens in new tab) Addiction Ayahuasca Cocaine use disorder Conditioned place preference +2

La patrimonialización del uso de ayahuasca en Perú

Ameryka Łacińska Kwartalnik analityczno-informacyjny October 30, 2025 Kinga Kowalczyk

El tema de este artículo es la patrimonialización de la ayahuasca en Perú, con especial atención a los aspectos legales de este proceso y la reconstrucción del debate que lo acompaña. Basándose en la bibliografía científica existente, se presenta una descrip-ción general de la ayahuasca y su uso por parte de los pueblos indígenas de América del Sur. A partir del análisis de actos jurídicos y...

DOI: 10.7311/20811152.2025.129.04 (opens in new tab) Ayahuasca

Severe Rhabdomyolysis and Acute Kidney Injury Following Ayahuasca‐Related Trauma: A Case Report

Underline Science Inc. October 7, 2025 American Medical Association 2025, Ashmeet Bedi

Background Ayahuasca, a traditional hallucinogenic brew, is a rare but emerging cause of rhabdomyolysis- induced acute kidney injury (AKI). Unlike more common etiologies of rhabdomyolysis, such as cocaine use or statin therapy, these patients may present without positive toxicology or relevant medication history. This case provides clinical insight into how individualized fluid and diuretic...

DOI: 10.48448/tdft-gm66 (opens in new tab) Rhabdomyolysis Acute kidney injury Myoglobinuria Anesthesia +8

Clinical pharmacology of ayahuasca: potential applications and future considerations

Expert Review of Clinical Pharmacology October 3, 2025 Lorena Terene Lopes Guerra, Isabella Caroline Da Silva Dias, Jaime E. C. Hallak et al. 2 citations

Similar to what happens with other psychedelics, there is an ongoing debate on subjective experience contribution to overall therapeutic mechanisms, which can depend on the targeted conditions. There are very few evidences from controlled studies, limiting the conclusions on safety and efficacy. On top of that, ayahuasca highly variable composition posits another challenge, and studies using...

DOI: 10.1080/17512433.2025.2577726 (opens in new tab) Clinical pharmacology Limiting Safety pharmacology Systems pharmacology +5

Ayahuasca: Pharmacological Composition and Potential Benefits

Research Journal of Pharmacy and Technology October 1, 2025 Raj Nashikkar, Shrikrishna Baokar, Rajendra Patil

Ayahuasca is a traditional hallucinogenic concoction utilised by indigenous populations in the Amazon Basin for ages in spiritual and therapeutic rituals. The increasing global popularity is attributed to its alleged medicinal and consciousness-expanding properties. The infusion is primarily composed of two key components: the Banisteriopsis caapi vine and the leaves of Psychotria viridis,...

DOI: 10.52711/0974-360x.2025.00731 (opens in new tab)